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Abstract Cryopyrin-associated periodic syndrome (CAPS)
is a rare hereditary inflammatory disorder encompassing a
continuum of three phenotypes: familial cold autoinflam-
matory syndrome, Muckle-Wells syndrome, and neonatal-
onset multisystem inflammatory disease. Distinguishing
features include cutaneous, neurological, ophthalmologic,
and rheumatologic manifestations. CAPS results from a
gain-of-function mutation of the NLRP3 gene coding for
cryopyrin, which forms intracellular protein complexes
known as inflammasomes. Defects of the inflammasomes
lead to overproduction of interleukin-1, resulting in
inflammatory symptoms seen in CAPS. Diagnosis is often
delayed and requires a thorough review of clinical
symptoms. Remarkable advances in our understanding of
the genetics and the molecular pathway that is responsible
for the clinical phenotype of CAPS has led to the
development of effective treatments. It also has become
clear that the NLRP3 inflammasome plays a critical role in
innate immune defense and therefore has wider implica-
tions for other inflammatory disease states.
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Introduction
Clinical Features
Cryopyrin-associated periodic syndrome (CAPS) is a rare
hereditary inflammatory disorder encompassing a continuum
of three phenotypes: familial cold autoinflammatory syndrome
(FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset
multisystem inflammatory disease (NOMID). These cryo-
pyrinopathies were once thought to be distinct conditions but
now are used to describe disease severity. FCAS is of the
mildest phenotype and was first reported in 1940 [1]. It is
characterized by recurrent urticaria, arthralgia, and fever after
general exposure to cold, not necessarily by touch [2, 3].
MWS is of the intermediate phenotype and was first
described in 1962 by Muckle and Wells [4], who determined
the condition to be inherited in an autosomal dominant
fashion. Inflammation can result spontaneously without
apparent provocation as well as from triggers such as cold,
stress, or exercise. In addition to the characteristics seen in
FCAS, MWS is characterized by renal amyloidosis, sensori-
neural hearing loss, and conjunctivitis [4]. The most severe is
NOMID and was first described in 1973 [5]. The hallmark of
NOMID is neonatal onset of cutaneous symptoms along with
end-organ damage. These include the “triad” of arthropathy,
chronic urticaria, and central nervous system (CNS) involve-
ment[6, 7]. CNS involvement can range from hearing loss to
chronic aseptic meningitis and mental retardation [8].
NOMID more commonly arises from de novo mutations
resulting from the early debilitating nature of this condition.
Distinctive features in CAPS can aid in identification.
Cutaneous manifestations include urticaria that is atypical.
It tends not to be pruritic, and patients instead describe the
affected skin as feeling “tight” and/or “warm.” The rash
usually appears on the trunk and limbs, with individual
lesions that are migratory and last less than 24 h (Fig. 1).
The morphology of the lesions includes faint pink figurate
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DOI 10.1007/s11882-010-0160-9erythema to juicy urticated papules and plaques, and there
is commonly a diurnal pattern, with rash severity increasing
in the evening [9], although in NOMID patients, the rash
may be present persistently. Neurological manifestations
can arise from increased inflammation, including head-
aches, hearing loss, raised intracranial pressure, and
meningitis [3]. Sensorineural deafness is progressive and
can occur in adolescence or adulthood [10, 11]. Examina-
tion reveals cochlear inflammation without any observed
amyloidosis in the Corti apparatus or cochlear nerve [12, 13].
In addition, autopsy of MWS patients with deafness
revealed atrophy of the cochlear nerve and a lack of the
Corti organ, suggesting the inflammation causes irreversible
damage, and pointing out the importance of early identifi-
cation and treatment [11]. Ophthalmologic manifestations
include conjunctivitis, uveitis, and papilledema. Rheumato-
logic manifestations, more specifically in NOMID, include
characteristic arthropathy affecting large joints such as the
knees,resultinginjointenlargementandfunctionaldisability.
This arises from abnormal endochondral ossification, which
causes the formation of calcified masses in the joints [14].
Lastly, systemic AA amyloidosis can occur in about 25% of
CAPS patients, commonly affecting the kidneys [8].
Pathogenesis
In all three phenotypes of CAPS, there is a gain-of-function
mutation of the NLRP3 gene (also known as CIAS1),
which is located on chromosome 1q44 and codes for
cryopyrin [15, 16]. However, as many as 40% of patients
with clinical NOMID do not show mutations on this gene,
implicating the involvement of other autoinflammatory
genes or the involvement of genetic mosaicism [17, 18].
Cryopyrin is among the nucleotide-binding domain, leucine
rich–containing (NLR) family of proteins, which serve an
important role in the regulation of the innate immune
response [19, 20]. In addition, cryopyrin forms intracellular
protein complexes known as inflammasomes that assist in
activating caspase-1 to cleave pro–interleukin (IL)-1β into
its mature form [21]. The defect in this pathway induces an
overproduction of IL-1β, leading to the inflammatory
symptoms seen in CAPS, and the success of IL-1 blockade
has helped confirm the role of IL-1β. Cryopyrin is expressed
inmonocytesandneutrophils,andisalsoexpressedinhuman
chondrocytes,accountingforthearthropathyseeninNOMID
[15, 22]. This is evident in the finding that monocytes in
CAPS patients have been shown to secrete more IL-1β [21].
This increase can be attributed to the monocytes of CAPS
patients that have impaired redox homeostasis and response
to oxidative stress, resulting in accelerated IL-1β secretion
[23]. However, the correlation of these findings with
mutations in NLRP3 requires further investigation.
Diagnostic Procedures
The rarity of CAPS and the overlap of symptoms with other
conditions often results in a delay in making the diagnosis.
Because of the varying degrees of severity in CAPS, a
thorough review of clinical symptoms is necessary, and a
combination of diagnostic procedures should be considered.
The following include laboratory assessments, skin biopsy,
and genetic testing.
Laboratory Assessments
Acute-phase protein levels should be monitored, including
C-reactive protein (CRP) and, if available, serum amyloid
A (SAA). Although no cutaneous signs may be present,
these inflammatory markers are normally elevated, often-
times greater than five times the reference range. Normal
CRP and SAA levels are rarely seen in CAPS, but if there
is doubt, serial measurements should be taken. Complete
blood counts typically reveal a slightly reduced hematocrit
and mild neutrophilia. Renal function should be recorded,
including a urinalysis to check for evidence of proteinuria.
If proteinuria is found, patients should be assessed for
nephrotic syndrome, a late complication of systemic
amyloidosis. For NOMID patients with neurological symp-
toms, cerebrospinal fluid (CSF) can be another diagnostic tool.
It has been reported in one patient with a novel NLRP3
mutation that cytokine levels in the CSF were elevated, but
serum levels remained normal [24]. In another case report, a
NOMID patient had normal inflammatory markers in the CSF
and serum; however, neopterin levels in the CSF were shown
to correlate with presentation of symptoms, suggesting
another possible marker of disease [25].
Skin Biopsy
Histologic examination of affected skin can assist in confirm-
ing an early diagnosis of CAPS. A common characteristic
Fig 1 Typical cryopyrin-associated periodic syndrome rash showing
figurate erythematous macules and urticated papules
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[9]. The infiltrate tends to be perivascular and also may be
peri-eccrine. This is consistent with the atypical urticaria
seen in CAPS patients, as the cellular infiltrate does not
consist of mast cells (Fig. 2).
Genetic Testing
A family of 14 NALP proteins has been identified, of which
NALP3 is included [26]. The NLRP3 gene contains nine
exons, with CAPS mutations predominantly localizing to
missense changes in exon 3 of the NACHT domain [16, 27,
28]. A total of 121 sequence variants have been identified
[29]. Conversely, CAPS patient have been identified who
do not have a mutation in NLRP3, and the clinical
presentations of CAPS patients with and without mutations
are very similar [7, 28]. The importance of sequencing the
whole NLRP3 gene is evidenced by missense mutations in
exon 4 (G755R, G755A) and exon 6 (Y859C) that have been
identified in CAPS patients [30, 31]. However, the currently
available commercial test by GeneDx (Gaithersburg, MD)
only sequences exon 3. It is likely that in the future, more
extensive sequencing analysis will be available to patients
diagnostically, as the cost will be reduced considerably due
to the availability of newer technologies.
Differential Diagnosis
Cold Contact Urticaria
Cold contact urticaria is the second most common physical
urticaria subtype, with as-yet-unknown etiology [32]. The
distinguishing feature is the development of urticaria and/or
angioedema on areas of the skin exposed to cold. This is
normally localized to sites of contact, but in some cases in
which a large area of skin is in contact (eg, swimming),
greatersystemicinvolvementcanoccur,includinggeneralized
urticaria, headache, dyspnea, hypotension, and loss of
consciousness [33]. A positive cold provocation test (ice
cube test) can confirm a diagnosis of cold contact urticaria.
An ice cube placed in a glove or plastic bag is applied to the
skin, and the test is positive if a wheal appears within 5 min.
The ice cube test is negative in CAPS, although cold
exposure may precipitate generalized rash and febrile
symptoms a few hours after contact [32].
Systemic-Onset Juvenile Idiopathic Arthritis/Adult-Onset
Still’s Disease
Systemic-onset juvenile idiopathic arthritis (SOJIA) and
adult-onset Still’s disease (AOSD) are rare, related inflamma-
tory disorders distinguished by age at onset, with AOSD
patients being 16 years of age or older [34]. SOJIA and
AOSD have characteristic features of polyarthritis/poly-
arthralgia, high fevers, leukocytosis with neutrophilia, and
evanescent skin rash that is nonpruritic and salmon colored
[35, 36]. Although the etiology is unknown, the effective use
of IL-1 antagonists in reducing symptoms helps provide
evidence for the role of IL-1 [34, 37]. Furthermore, SOJIA/
AOSD have similar symptoms and signs as CAPS patients,
as demonstrated by the multisystem inflammation and by the
raised levels of acute-phase proteins [38, 39]. SOJIA and
AOSD are frequently diagnoses of exclusion once under-
lying autoimmune, infectious, or paraneoplastic disorders
have been ruled out [40]. It is important to consider CAPS,
although patients with CAPS typically present in infancy or
childhood and do not have a relapsing/remitting course.
Deficiency in Interleukin-1 Receptor Antagonist
Deficiency in IL-1 receptor antagonist (DIRA) is a rare
autoinflammatory disease in which a deletion in the IL1RN
gene,locatedonchromosome2,resultsinalossofproduction
of the naturally occurring IL-1 receptor antagonist (RA) [41].
This loss of IL-1 RAresults in a functional excess of the
proinflammatory cytokines IL-1α and IL-1β. The clinical
phenotype is similar to that of severe CAPS (NOMID
spectrum). DIRA presents early in childhood with joint pain
and enlargement, neutrophilic dermal infiltrate on histologic
examination, and elevated levels of acute-phase reactants
such as CRP. Clinically, the most important distinguishing
feature in DIRA is a pustular rash similar to pustular
psoriasis, as opposed to the urticarial eruption of CAPS.
DIRA patients who have had a therapeutic trial with
anakinra have shown a dramatic and sustained improvement
in their clinical signs and a normalization of their acute-
phase response [42].
Fig 2 Skin biopsies showing perivascular and periadnexal neutro-
philic infiltration within the dermis
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Schnitzler syndrome is a rare disorder characterized by
chronic urticarial rash and monoclonal gammopathy, along
with fever, arthralgia, or bone pain [43]. Although the
pathophysiology is presently unknown, the clinical improve-
ment seen in these patients treated with IL-1 antagonists
implies an autoinflammatory process [44]. In many respects,
the clinical presentation is very similar to that of CAPS.
Both conditions show chronic, nonpruritic urticarial lesions,
and upon histologic examination show neutrophilic inflam-
mation. The age at onset differs, with Schnitzler syndrome
presenting at a much older age (mean age at onset, 60 years)
[45]. In addition, by definition, Schnitzler syndrome patients
have a monoclonal gammopathy that has not been reported
in CAPS.
Treatment
Conventional Anti-inflammatories
Many anti-inflammatories, immunosuppressants, and anti-
histamines have been tried to control the symptoms and
signs seen in CAPS. These include methotrexate, cyclo-
sporine, azathioprine, cyclophosphamide, and tumor necro-
sis factor blockers, all of which have been disappointing.
Modest improvements with high-dose oral corticosteroids
and thalidomide have offered some patients partial symp-
tom control but have not been tolerated due to their adverse
side effect profile [8]. The lack of effective treatments
necessitated the need for development of more targeted
therapies.
Interleukin-1 Targeted Therapy
The identification of the NLRP3 gene responsible for FCAS
a n dM W Sa n dt h ef i n d i n gt h a tI L - 1 β production is
increased in NOMID has created an important therapeutic
target for CAPS [16, 28]. In addition, as IL-1 induces an
increase in SAA levels, alleviating high levels of IL-1 can
help prevent the development of systemic amyloidosis and
lessen the potential for end-organ disease [46]. In the past
7 years, three drugs have shown efficacy in targeting IL-1β
for CAPS patients. Each is unique in its strategy, but all
have been shown to be effective in alleviating clinical
symptoms.
Anakinra: Interleukin-1 Receptor Antagonist
IL-1 is a ubiquitous proinflammatory cytokine that has been
implicated in many diseases (eg, septic shock, rheumatoid
arthritis, and gout) [47–49]. It consists of two isoforms (α
and β), and its effects are moderated by the competitive
binding of the IL-1 receptor by naturally occurring IL-1
RA. Anakinra is a recombinant form of IL-1 RA that has a
short half-life of 4 to 6 h [50]. Anakinra was originally
developed as a treatment for septic shock [51]. An open-
label study involving 99 patients suggested that anakinra
might be beneficial in the treatment of sepsis; however, a
subsequent, randomized, double-blind, placebo-controlled
study with 893 patients found no significant difference
between the groups [52, 53]. However, preliminary studies
in patients with rheumatoid arthritis found that daily
injections of anakinra were effective in alleviating symp-
toms, and double-blind, placebo-controlled studies demon-
strated its efficacy and safety [48, 54, 55]. It was approved
by the US Food and Drug Administration for the treatment
of rheumatoid arthritis in 2001. In the first case report for
anakinra and CAPS, two MWS patients were given daily
100-mg injections and showed a reduction in symptoms
within hours [56]. Following this, several case reports and
studies demonstrated the efficacy of anakinra in CAPS [57–
60]. These findings provided the basis for larger studies.
In a prospective study, 18 NOMID patients were
recruited to receive daily, subcutaneous, 1-mg/kg of body
weight injections of anakinra [12]. All patients showed two
of the following symptoms: urticarial rash, CNS involve-
ment, or epiphyseal or patellar overgrowth. Patients ranged
from 4 to 32 years of age. Efficacy assessments were made
at months 1, 3, and 6 from the first injection. At month 3,
patients who showed treatment response discontinued the
anakinra until they presented with a clinical flare, although
this withdrawal phase was subsequently discontinued due
to the severity of disease flares seen in the initial patients.
After theappearanceofclinical flares, patientsrecommenced
anakinra and were followed up to 24 months. Primary
outcomes were CRP and SAA levels as well as daily ratings
of symptoms. All patients showed a disappearance of
urticarial rash within 3 days, and CRP/SAA levels showed
dramatic decreases after 1 month that were sustained. In
total, 8 patients showed remission of inflammatory symp-
toms after 3 months, with the remaining 10 patients showing
remission after 6 months. The 11 patients who underwent
withdrawal of anakinra relapsed after a median of 5 days.
These patients all achieved remission when recommencing
the anakinra. Furthermore, treatment with anakinra reduced
progressively both spontaneous and stimulated secretion of
IL-1β from cultured patients’ peripheral blood mononuclear
cells after 6 months of therapy. Transcript levels of IL-1β
and genes downstream of IL-1β also fell while the patients
were on treatment. No patient discontinued treatment, and
the most common adverse events were injection site
reactions and upper respiratory infections.
These results were corroborated by a retrospective
review of 22 patients with CAPS [8]. Primary outcomes
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well as review of clinical symptoms. Of these patients, 15
were treated with anakinra, starting with daily 100-mg
subcutaneous injections and then reduced to 20 to 50 mg in
order to determine efficacy at lower doses. The two children
involved in the study continued to receive 100 mg daily. All
15 patients showed complete remission of disease activity
within 12 h of anakinra injections, with 6 patients showing
remission after 4 h. Levels of CRP and SAA returned to
normal after 1 week in all patients. During this time, five
patients briefly stoppedtreatment and showed a reappearance
of symptoms after only 36 to 48 h, providing more evidence
for the importance of daily injections. All patients tolerated
the treatment well, except for injection site reactions.
Anakinra was a major advancement in the management of
CAPS, as no other treatment had been effective previously.
However, despite the success of anakinra, the short half-life
requires daily injections, leading to sometimes-painful
injection site reactions. Although it was never US Food and
Drug Administration approved for use in CAPS, anakinra
continues to be used effectively as an off-label treatment. In
addition, the efficacy of anakinra is being explored in other
disorders,suchasrheumatoidarthritis(NCT00213538),renal
disease (NCT00420290, NCT00897715), type 1 diabetes
(NCT00711503), SOJIA (NCT00339157), and atopic der-
matitis (NCT01122914). Treatment with anakinra has been
reported to be beneficial for other disorders, such as
Schnitzler syndrome, adult-onset Still’s disease, and even in
the prevention of heart failure after acute myocardial
infarction [61–63].
Rilonacept: Interleukin-1 Trap
Cytokine inhibition has been effective with certain cyto-
kines (eg, with tumor necrosis factor-α blockers such as
etanercept); however, inhibition of IL-1 was much more
difficult because of the complexity of its receptor system
[64]. The development of cytokine trap technology has
allowed for successful inhibition because these multicom-
ponent “traps” contain binding sites for the cytokine as well
as their accessory proteins. Thus, cytokine traps are useful
in autoinflammatory conditions because they have been
shown to effectively bind to their respective cytokines with
high affinity [64].
Rilonacept was created using cytokine trap technology.
It is a dimeric fusion protein that contains binding regions
for the type 1 receptor and the IL-1 receptor accessory
protein, and it is fused to the Fc portion of human IgG1
[65]. In 2008, it was the first US Food and Drug
Administration–approved drug therapy for CAPS, specifi-
cally for FCAS and MWS in adults and children 12 years of
age and older. Rilonacept has a circulating half-life of
8.6 days [66]. This makes weekly subcutaneous injections
of rilonacept a major improvement over the daily injections
of anakinra; however, the monthly cost of anakinra is still
much lower than that of rilonacept.
An open-label pilot study of rilonacept was performed,
with five FCAS patients having confirmed mutations [67].
At baseline, all patients were given a 300-mg loading dose
of rilonacept and were not dosed again until disease flares
occurred. Disease flares were defined as a greater than 50%
increase in acute-phase protein levels. After a flare
occurred, patients were again dosed with 300 mg, followed
by weekly 100-mg doses. If complete remission of
symptoms, defined by levels of CRP and SAA, had not
occurred, the patients would then be eligible for dose
escalation. The first dose increase was 160 mg. If remission
did not occur after 4 weeks at this dose, patients were
eligible for another increase, to 320 mg. All patients who
reached a dose of 160 mg were then monitored for 2 years.
In response to the baseline dose, all five patients showed
improvement of symptoms, with maximum improvement at
day 10 for four patients and at day 6 for one patient.
Disease flares occurred within a range of 10 to 28 days
from the initial loading dose. All five patients continued to
the extension phase and were dosed at 160 mg weekly.
Remission did not occur in four patients, and they were
then dosed at 320 mg. These four patients reported
subjective improvement of symptoms; however, acute-
phase reactant levels were not significantly different as
compared with the 160-mg dose. All five patients tolerated
the drug very well with no injection site reactions. Adverse
events reported by patients were only mild to moderate.
The first randomized, double-blind consecutive studies
of any treatment for CAPS were completed in 2008, with
47 patients having confirmed NLRP3 mutations [68]. The
first study consisted of a 6-week, randomized, double-blind,
controlled period, with 23 patients receiving 160-mg
weekly injections and 24 patients serving as controls. At
the end of this 6-week treatment period, patients receiving
rilonacept had a remarkable reduction in symptoms,
including lower levels of CRP and SAA. The second study
immediately followed the first and consisted of two parts.
Part A included 46 patients from the first study and
consisted of a single-blind, 9-week period with 160-mg
weekly injections. Part B was a randomized, double-blind,
9-week withdrawal period. Patients receiving placebo in the
first study showed rapid and significant improvement
during part A of the second study. In part B, patients
receiving placebo showed a gradual return of symptoms,
while patients receiving rilonacept continued to show a
decrease in symptoms. These studies demonstrated that
rilonacept was generally well-tolerated; the most frequent
adverse events were injection site reactions, upper respira-
tory tract infections, headache, arthralgia, and diarrhea. One
older adult patient died after developing sinusitis and
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study investigators thought that the death was unrelated to
rilonacept. The authors concluded that there may be
potential risk of serious infections for patients on targeted
IL-1 therapy.
In addition to CAPS, rilonacept has been investigated for
the treatment of other indications. A single-blind pilot study
has been completed among 10 patients with gouty arthritis,
showing that rilonacept could be an effective treatment
[69]. Currently, a larger, randomized, double-blind study is
being conducted to ascertain the effectiveness of rilonacept
in gout (NCT00856206). Other clinical trials are currently
investigating the effectiveness of rilonacept in diabetes
mellitus type 1 (NCT00962026) and juvenile idiopathic
arthritis (NCT00534495).
Canakinumab: Interleukin-1β Monoclonal Antibody
Canakinumab is an IL-1β fully human, monoclonal
antibody that is specific for IL-1β and not other members
of the IL-1 family. The development of this compound has
allowed for the improved detection of circulating levels of
IL-1β in vivo and, more importantly, the elucidation of the
biology of IL-1β. The use of canakinumab in CAPS
patients has shown that the release of IL-1β is driven by
a positive feedback loop triggered by IL-1β, and that the
level of IL-1β production is correlated with disease severity
[70]. Canakinumab has a mean half-life of 26 days, which
allows a dosing schedule of a subcutaneous injection every
8 weeks [71]. This dosing schedule compares favorably
with that of anakinra (daily) and rilonacept (weekly). It
received US Food and Drug Administration approval for
use in CAPS patients—adults and children older than
4 years of age with FCAS and MWS—in June 2009.
The first open-label clinical trial for canakinumab was
completed in 2008 with seven mutation-confirmed CAPS
patients [70]. The first four patients were dosed at 10 mg/kg
intravenously, and time until relapse was noted. After
relapse, another dose of 1 mg/kg intravenously was
administered, and time to relapse was again noted. From
this point, each patient was dosed 150 mg subcutaneously
after each relapse. An additional three patients were
enrolled and initially treated with 150 mg and again at
relapse. Levels of circulating canakinumab were deter-
mined using enzyme-linked immunosorbent assay. The first
four patients dosed had their urticarial symptoms disappear
after just 1 day, and a complete clinical response—as
defined by a lack of skin rash and joint pain, improvement
of arthralgia, and normal laboratory values—was achieved
after 1 week. At the 10-mg/kg intravenous dose, relapse did
not occur until a median time of 185 days. At the 1-mg/kg
intravenous dose, relapse did not occur until a median of
90.5 days. With the 150-mg subcutaneous dose, the median
duration of clinical remission was 127 days (range, 55–
230 days). In these patients, IL-1β production fell to levels
similar to those seen in unaffected healthy controls after
8 weeks of therapy. These exploratory findings provided
the foundation for the next trial.
The first double-blind, randomized trial was completed
in 2008 [72￿]. It consisted of a 3-part, 48-week, withdrawal
study with 35 CAPS patients. Part one of the study
consisted of an 8-week period with a single open-label
dose of canakinumab; adults received 150 mg and children
were dosed at 2 mg/kg body weight if they weighed less
than 40 kg. Part two consisted of a 24-week, double-blind
withdrawal period in which patients who completed part
one received canakinumab or placebo every 8 weeks. At the
end of part two or at clinical relapse, patients entered part
three, which consisted of an open-label administration of
canakinumab every 8 weeks for a minimum of 16 weeks.
All patients had confirmed NLRP3 mutations, were between
4 and 75 years of age, weighed at least 15 kg, and were
allowed to enroll immediately after discontinuation of other
CAPS treatments. Of the 35 patients who entered into the
study at part one, 34 had a complete response, defined by
physician assessments of disease activity and rash, as well
as CRP and SAA levels. Most patients achieved a complete
response by day 8. For part two, 31 patients were continued
on study, with 15 patients receiving drug and 16 receiving
placebo. All patients in the treatment group continued in
remission of symptoms, while 13 in the placebo group had
disease flares, including elevated levels of CRP and SAA.
All 31 patients continued on to part three of the study, with
29 continuing to completion.The results showed sustained
clinical remission with minimal disease activity, absence of
rash, and levels of CRP and SAA within the reference
range. Canakinumab was tolerated well, with only two
patients reporting serious adverse events, which included an
episode of vertigo followed by acute close-angle glaucoma
related to complications of CAPS, and a recurrent lower
urinary tract infection and sepsis. The most commonly
reported adverse events among those on drug were naso-
pharyngitis, rhinitis, nausea, diarrhea, and vertigo. Most
patients did not report any injection site reactions.
Canakinumab has shown efficacy as a treatment for
other conditions, including rheumatoid arthritis and gout
[73, 74]. The effectiveness of this drug is currently being
explored in other inflammatory conditions, including
SOJIA (NCT00886769) andosteoarthritis (NCT01160822),
as well as in metabolic disorders such as type 2 diabetes
mellitus (NCT00900146).
Caspase-1 Targeted Therapy
Caspase-1 inhibitors act upstream in this IL-1β produc-
tion pathway. The drug VX-765 (Vertex Pharmaceuticals,
Curr Allergy Asthma Rep (2011) 11:12–20 17Cambridge, MA) is a powerful selective inhibitor of
caspase-1. In vitro and animal models have shown VX-765
to reduce levels of IL-1β in a dose-dependent manner [75].
Another study showed that IL-1β secretion in peripheral
blood mononuclear cells isolated from FCAS patients was
greatly inhibited by VX-765 [76]. Despite these findings,
no clinical trials have been registered involving CAPS
patients; however, a phase 2 trial of VX-765 for the treat-
ment of psoriasis (NCT00205465) was completed in 2005,
and another phase 2 trial for the treatment of epilepsy is
currently being conducted (NCT01048255). Further inves-
tigation is required to determine efficacy in CAPS patients.
Quality-of-Life Assessments
Traditional quality-of-life surveys have been used to assess
CAPS patients, and they are useful in understanding the full
impact of the disease on the patient, as well as assessing
response to treatment. These include the Medical Outcomes
Survey Short Form 36, Health Assessment Questionnaire,
Functional Assessment of Chronic Illness Therapy Fatigue
Scale, and the Child Health Questionnaire-Parent Form.
Because of the variable nature of symptoms and severity in
CAPS, it is often difficult to accurately assess the quality of
life of CAPS patients. Daily health assessment forms have
been developed that reliably capture disease severity or
symptomsandcanbeusedtomeasuretreatmentefficacy[77].
Conclusions
Remarkable advances have been made in our understanding
of the genetics and the molecular pathway that is
responsible for the clinical phenotype of CAPS. The
discovery of mutations in the NLRP3 gene coupled with
elucidation of IL-1 biology has led to rational targeted
therapy for this rare disease. Therapy offers rapid and
sustained clinical remissions for the vast majority of CAPS
patients. All three agents appear to be well-tolerated with a
relatively safe side effect profile. It also has become clear
that the NLRP3 inflammasome plays a critical role in innate
immune defense and therefore has wider implications for
other inflammatory disease states. Mutations in NLRP3 are
not unique to CAPS patients, as they have been identified
in other diseases (eg, gout) [78]. In addition, involvement
of the inflammasome in disease is suspected in a variety of
conditions, such as pyoderma gangrenosum, type 2 diabetes
mellitus, and atherogenesis, which offers other clinical
targets for IL-1 directed therapy [79–81].
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